Search Results
Showing Results for liver metastases
Dr Satish Nadig describes Northwestern Medicine’s first use of the RAPID procedure to treat metastatic colorectal cancer with liver transplantation. He outlines the innovative surgical techniques, the promise of the CLEAR program, and the future potential of machine perfusion technology to extend transplant opportunities to more patients.
What’s new in GI oncology? With the 2025 ASCO Gastrointestinal Cancers Symposium still fresh in our minds, we hear from leading experts on the key abstracts and presentations from the conference in the fields of colorectal and pancreatic cancer. Circulating ...
Metastatic castration-resistant prostate cancer (mCRPC) represents the most formidable stage of prostate cancer (PCa) and is responsible for the majority of PCa-related mortalities. This advanced form of the disease typically evolves from less aggressive stages.1 PCa is broadly categorized into ...
The ESMO GI 2024 meeting, held this year in Munich, Germany, brought together researchers and clinicians from around the world to discuss recent developments in gastrointestinal malignancies.
Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (...
Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) designed to effectively deliver a potent topoisomerase I inhibitor (exatecan derivative) to HER2-expressing cancer cells and limit potential systemic toxicity.1 T-DXd has ...
Gastric and gastro-oesophageal junction (GOJ) adenocarcinomas are highly aggressive tumours with an overall poor prognosis, which is primarily attributable to the late stage of diagnosis resulting from nonspecific symptoms.1,2Â While curative surgical resection is recommended for early-stage cases,3Â advanced disease ...
Cancers of the anal canal are relatively uncommon, and account for less than 1% of all new cancer diagnoses in the UK.1 However, the incidence of these cancers has increased over the past decade, primarily in females, in which they have ...
Bladder cancer is one of the most common malignancies in the USA, with an estimated 81,180 new cases and 17,100 deaths in 2022.1 Advanced urothelial carcinoma (aUC) includes both locally advanced, unresectable and metastatic urothelial cancer. About 5% of all bladder cancer cases present ...
Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) ...
Triple-negative breast cancer (TNBC) is a biologically aggressive form of breast cancer defined by the absence of the oestrogen receptor and progesterone receptor, as well as lack of amplification of the human epidermal growth factor receptor 2 (HER2). TNBC accounts for ...
Androgen deprivation therapy (ADT) has been the cornerstone of the treatment of metastatic prostate carcinoma for over 70 years, ever since Huggins and Hodges first treated men with prostate carcinoma with orchidectomy or oestrogen injection in 1941.1Â However, the treatment landscape of ...
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1Â CCAs tend to metastasize and have early lymph node ...
To date, the cornerstone of curative treatment in early-stage gastrointestinal (GI) cancers includes surgery and sometimes radiation therapy. Depending on the stage and tumour type, these approaches are often combined with systemic neoadjuvant or adjuvant therapies. After all definitive therapy ...
RELATIVITY-047 reported on the initial efficacy and safety of relatlimab (RELA), an antibody to lymphocyte-activating gene 3 (LAG-3), in combination with nivolumab (NIVO), an antibody to programmed cell death 1 (PD-1).1Â These positive findings add to the existing evidence for the efficacy ...
Choriocarcinoma of the testes is very rare, occurring either in pure form or as part of mixed germ cell tumor.1,2Â Pure choriocarcinoma constitutes <1% of choriocarcinoma cases, whereas mixed tumors with choriocarcinoma make up 8% of testicular germ cell tumors.2Â The ...
Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
